EASD 2025 15 - 19 September 2025

Incidence of non-arteritic ischaemic optic neuropathy (NAION) across completed phase 2, 3 and 4 trials evaluating the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

Diabetes

Congress oral presentation

GLP-1 RA

Liraglutide

Semaglutide

PHASE 3 (RCT)

Are you a healthcare professional?